肝细胞生长因子在损伤肾组织中的作用

肝细胞生长因子（hepatocyte growth factor．HGF）是一种多效性生长因子,主要由间质细胞产生,通过自分泌和旁分泌方式作用于上皮细胞、内皮细胞以及间质细胞本身,具有促有丝分裂、促细胞形态形成和调节细胞活动的功能,从而对损伤的器官和组织进行修复。许多新的研究显示,在急性肾损伤时给予外源性HGF可以保护肾小管上皮细胞、重建肾小管结构和维持肾功能完整性。此外,HGF还能有效地抑制与慢性肾脏疾病及慢性肾功能衰竭密切相关的肾间质纤维化的进展过程。     

肝细胞生长因子对主要器官/组织损伤的修复作用

肝细胞生长因子(HGF)是一种多功能的生长因子,它参与多种细胞的增殖、迁移和形态发生。HGF对多种成熟的器官／组织有营养修复作用,促进肝、肾、肺等损伤器官的再生,同时也是神经系统新的营养因子之一。本综合近年来有关献对HGF在主要器官或组织损伤中的修复作用作一概括性介绍。     

β-转化生长因子与肝细胞生长因子在肾间质纤维化中的关系

肾间质纤维化是各种慢性肾脏疾病的最终通路。研究发现,β-转化生长因子与肝细胞生长因子的平衡关系可能在肾间质纤维化发生发展过程中起着重要作用。     

在肾癌细胞系GRC-1细胞周期不同阶段Wnt-5A基因的表达情况

Wnt基因所编码的蛋白质与许多生长因子一样具有分泌型生长因子的结构特点,其家族成员Wnt-5A是许多恶性肿瘤的自分泌生长因子,在肾细胞癌中表达显著升高.为研究在细胞周期的不同阶段生长因子Wnt-5A在转录水平的表达情况,我们采用胸腺嘧啶双阻断及高压笑气处理的方法,使肾细胞癌细胞系GRC-1细胞同步化.用半定量反转录多聚酶链反应对处于细胞周期不同阶段的细胞cDNA进行扩增,S期与G1,M期Wnt-5A mRNA表达存在差异显著(P＜0.05）.结果提示生长因子Wnt-5A在肾细胞癌的发生中具有潜在的作用,在S期作用可能尤为显著.     

上皮—间质转化在肾间质纤维化中的作用

上皮－间质转化在发育和纤维化过程中具有重要作用。本文综述了上皮－间质转化发生的过程及其机制的研究进展,尤其是细胞外基质、生长因子、粘附分子及基因对上皮－间质转化的影响。并就在肾间质纤维化过程中因上皮－间质转化致成纤维细胞增多,从而导致肾纤维化的可能作用及其影响因素作一述。     

表皮形态发生素(Epimorphin)与表皮形态发生

表皮形态发生素（epimorphin 又称为syntaxin2）是哺乳动物中高度保守的一个间质细胞表面膜蛋白,胞外区包含有1个19个氨基酸残基的部位（NL肽序列）,是其与细胞的结合位点,但发挥效应必须有其它的胞外区存在.目前,已经发现它调控下游的2个分子MMP3和C/EBPβ,但对于其信号通路还知之甚少,推测其可能通过直接或者间接磷酸化表皮生长因子受体（EGFR）而激发MAPK/ERK信号通路.它在多种表皮组织（包括肺、肠、肝、乳腺、胰腺、毛囊、胆囊、血管内皮等）的表皮形态发生,尤其是腺管状结构的形态发生过程中发挥重要作用.依靠极性和非极性2种不同的表达方式,epimorphin可以选择性介导腺管形态发生的2个关键过程:分支形态发生和腔形态发生,分支状形态发生涉及到腺管的发生和延展,腔形态发生涉及到腺管直径的增大.     

外加直流电场对血管平滑肌细胞形态及迁移行为的影响

在外加直流电场(electricalfields,EFs)作用下血管平滑肌细胞(VSMCs)膜表面细胞生长因子受体表达发生明显的变化,并影响细胞形态、迁移的特性。通过EFs干预装置干预体外培养的大鼠主动脉VSMCs,记录和分析细胞图像,研究不同强度电场、不同作用时间下VSMCs迁移和细胞形态的变化,并用免疫细胞化学或免疫荧光染色方法检测与VSMCs迁移相关的血小板衍化生长因子受体(PDGFR)、血管紧张素II1型受体(AT1R)和2型受体(AT2R)等受体的表达情况,研究EFs影响VSMCs形态及迁移的机制。研究结果提示,在EFs干预作用下,VSMCs膜PDGFR表达增加,部分细胞呈不对称分布,在EFs阴极面较集中;细胞中AT1R表达亦增加,但无明显不对称分布现象;AT2R表达没有改变;EFs长时间作用下,培养的VSMCs有明显的电场趋化性,细胞向阴极迁移的距离明显高于无EFs作用对照组,细胞膜向阴极方向伸展,发生形状改变,定向迁移依赖于EFs强度。EFs作用下,部分细胞生长因子受体的表达上调和重分布,可能与细胞定向迁移的启动和维持有关。     

FGF9与FGFR3受体在骨发育与疾病中的作用

成纤维细胞生长因子9(fibroblast growth factor,FGF9)最初发现于人类神经胶质瘤细胞,是成纤维细胞生长因子家族的成员之一.研究发现FGF9在多种组织的发育及疾病的发生中起重要作用.FGF9与肝素结合活化FGFR3受体,可作用于软骨细胞,在骨骼发育及损伤过程中抑制软骨细胞增生和软骨内骨化.FGF9基因缺失或突变可分别导致骨骼发育不良或肿瘤.本文简要综述FGF9与FGFR3受体在骨发育中的作用及其致病机制的研究进展.     

转化生长因子β及其生物学效应

转化生长因子β（ＴＧＦβ）属于一处多功能多肽家族,在免疫抑制、抗炎症反应、对增殖和细胞间质产生的调控、损伤修复等方面起重要作用。ＴＧＦβ表达和信号转导失常与多处疾病的发生有关。     

ADAMs与生长发育

ADAMs是近几年发现和鉴定的一类具有多个结构域和广泛生物学功能的细胞表面糖蛋白,由信号肽区、前调控区、金属蛋白水解酶区、去整合蛋白区、富半胱氨酸区、表皮生长因子区、跨膜区和细胞质区组成,已发现30多种成员。它们在性细胞发生、受精、胚胎发育、细胞融合、器官形成、细胞分化等方面起重要作用。本文重点介绍了ADAM10／Kuz在神经发育过程中的信号传导和蛋白水解酶作用及ADAM17／TACE、ADAMTS在小鼠胚胎发育过程中对眼、肾、肾上腺、生殖等器官结构、功能的作用;另外,还对ADAM12／meltrin α促进肥细胞融合、分化、MIG－17介导细胞迁移等多种ADAMs在生长发育方面的研究作了简要介绍。     

Zymogen factor IX potentiates factor IXa-catalyzed factor X activation

Intrinsic factor X activation is accelerated >10(7)-fold by assembly of the entire complex on the activated platelet surface. We have now observed that increasing the concentration of zymogen factor IX to physiologic levels ( approximately 100 nM) potentiates factor IXa-catalyzed activation of factor X on both activated platelets and on negatively charged phospholipid vesicles. In the presence and absence of factor VIIIa, factor IX (100 nM) lowered the K(d,appFIXa) approximately 4-fold on platelets and 2-10-fold on lipid vesicles. Treatment of two factor IX preparations with active-site inhibitors did not affect these observations. Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface. Since plasma concentrations of prothrombin, factor VII, protein C, or protein S did not by themselves potentiate factor Xa generation and did not interfere with the potentiation of the reaction of factor IX, the effect is specific for factor IX and is not attributable to the Gla domain of all vitamin K-dependent proteins. These observations indicate that under physiologic conditions, plasma levels of the zymogen factor IX specifically increase the affinity of factor IXa for the intrinsic factor X activation complex.     

Lipid-bound factor Xa regulates tissue factor activity

The activation of coagulation factor X by tissue factor (TF) and coagulation factor VIIa (VIIa) on a phospholipid surface is thought to be the key step in the initiation of blood coagulation. In this reaction, the product, fXa, is transiently and reversibly bound to the TF-VIIa enzyme complex. This in effect leads to a probabilistic inhibition of subsequent fX activations; a new fX substrate molecule cannot be activated until the old fXa molecule leaves. In this study, we demonstrate that benzamidine and soybean trypsin inhibitor-conjugated Sepharose beads, which bind fXa and sequester it away from the reaction, serve to enhance fX activation by the TF-VIIa complex. Thus, removal of fXa from the reactive zone, by either flow, fXa sequestration, or binding to distant lipid surfaces, can serve to enhance the levels of TF-VIIa activity. Using resonance energy transfer, we found the dissociation constants of fX and fXa for 100 nm diameter phospholipid vesicles to be on the order of 30-60 nM, consistent with previous measurements employing planar lipid surfaces. On the basis of the measurements of binding of fXa to phospholipid surfaces, we demonstrate that the rates of fX activation by the TF-VIIa complex under a variety of experimental conditions depend inversely on the amount of product (fXa) bound to the TF-phospholipid surface. These data support an inhibitory role for the reaction product, fXa, and indicate that models previously employed in understanding this initial coagulation reaction must now be re-evaluated to account for both the product occupancy of the phospholipid surface and the binding of the product to the enzyme. Moreover, the inhibitory properties of fXa can be described on the basis of the estimated surface density of fXa molecules on the TF-phospholipid surface.     

Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.

The activation of factor X by factor IXa (fIXa) in the presence of phosphatidylcholine-phosphatidylserine (PCPS) vesicles is markedly accelerated by thrombin-activated factor VIII (fVIIIa). The interaction between highly purified fVIIIa and fIXa in this complex was studied fluorometrically at 25 degrees C by using a derivative of D-phenylalanyl-prolyl-arginyl-fIXa which was modified at the active site with fluorescein-5-maleimide (Fl-M-FPR-fIXa). Titration of Fl-M-FPR-fIXa with fVIIIa at fixed PCPS resulted in a large, saturable increase in anisotropy (delta r = 0.09). The titration data were fit to a model assuming a reversible equilibrium between fVIIIa and fIXa, resulting in an apparent dissociation constant of 2 nM and a stoichiometry of 1 mol of fVIIIa/mol of Fl-M-FPR-fIXa. The initial velocity of factor X activation was measured under identical conditions except that active fIXa and factor X were included, which yielded binding parameters similar to those determined fluorometrically. Thus, the fluorescence method accurately reflects complex formation between fVIIIa and fIXa on the phospholipid surface, and the fVIIIa-fIXa interaction is not influenced by the presence of the substrate, factor X. Addition of fVIII to Fl-M-FPR-fIXa and PCPS produced a small, saturable increase in anisotropy (delta r = 0.03), followed by a larger increase (delta r = 0.07) upon addition of thrombin to activate fVIII. Thus, fVIII binds fIXa, but proteolytic modification of fVIII must occur before the complete fVIIIa-dependent structural change in the active site of fIXa, as reflected in the anisotropy change, occurs     

Escherichia coli elongation factor G blocks stringent factor

The relationship between the binding domains of elongation factor G(EF-G) and stringent factor (SF) on ribosomes was studied. The binding of highly purified, radioactively labeled, protein factors to ribosomes was monitored with a column system. The data show that binding of EF-G to ribosomes in the presence of fusidic acid and GDP or of the noncleavable analogue GDPCP prevents subsequent binding of SF to ribosomes. In addition, stabilization of the EF-G-ribosome complex by fusidic acid inhibits SF's enzymatic activities. Removal of protein L7/L12 from ribosomes leads to weaker binding of EF-G, while SF's binding and activity are unaffected. In the absence of L7/L12, EF-G-dependent inhibition of SF binding and function is reduced. The data presented in this report suggest that these two factors bind at overlapping, or at least interacting, ribosomal domains.     

Inactivation of factor VIII by factor IXa.

Factor VIII (FVIII) is the nonproteolytic cofactor for FIXa in the tenase complex of blood coagulation. FVIII is proteolytically activated by thrombin and FXa in vitro to form a heterotrimer with full procoagulant activity. Activated protein C inactivates thrombin-activated FVIII through cleavage adjacent to position Arg 336 in the cofactor. We have investigated the interaction of FIXa and FVIII and subjected FVIII polypeptides to N-terminal amino acid sequence analysis. Contrary to previous reports, we were unable to demonstrate the activation of FVIII by FIXa. Incubation of these two proteins at equimolar or close to equimolar concentrations resulted in the inactivation of FVIII, coincident with cleavage of the FVIII heavy chain adjacent to Arg 336 and the light chain adjacent to Arg 1719. These cleavages were detected in the presence or absence of thrombin, indicating that FIXa does not stabilize thrombin-activated FVIIIa. APC cleaved FVIII at the same position in the heavy chain, and simultaneous incubation of FVIII, APC, and FIXa did not result in stabilization of the cofactor. We conclude that FIXa does not play a role in the stabilization or activation of FVIII.